Royalty Pharma plc Debt Securities, Available-for-sale, Amortized Cost
Royalty Pharma plc (RPRX) had Debt Securities, Available-for-sale, Amortized Cost of $367.88 million as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-02-11
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $367.88M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $265.78M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $267.12M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $197.73M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-12-31 | $367.88M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $265.78M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $267.12M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $197.73M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $504.03M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $500.25M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $501.45M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $352.62M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $352.37M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $352.10M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $350.00M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $350.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $350.00M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $575.42M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $269.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $262.42M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $204.51M 10-K · filed 2023-02-15 | |
| 2021-09-30 | $192.10M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $178.38M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $142.71M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $145.65M 10-K · filed 2022-02-15 | $125.12M 10-K · filed 2021-02-24 |
| 2020-09-30 | $125.12M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $125.12M 10-Q · filed 2020-08-12 | |
| 2019-12-31 | $125.12M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |